Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Christiane ThallingerEdgar Selzer

Abstract

Little is known about the role that Mcl-1, an antiapoptotic Bcl-2 family member, plays in solid tumor biology and susceptibility to anticancer therapy. We observed that the Mcl-1 protein is widely expressed in human sarcoma cell lines of different histological origin (n = 7). Because the expression of antiapoptotic Bcl-2 family proteins can significantly contribute to the chemoresistance of human malignancies, we used an antisense strategy to address this issue in sarcoma. SCID mice (n = 6/group) received s.c. injections of SW872 liposarcoma cells. After development of palpable tumors, mice were treated by s.c.-implanted miniosmotic pumps prefilled with saline or antisense or universal control oligonucleotides (20 mg/kg/day for 2 weeks). On days 2, 6, and 10, mice were treated with low-dose cyclophosphamide (35 mg/kg i.p) or saline control. During the experiments, tumor weight was assessed twice weekly by caliper measurements. On day 14, animals were sacrificed. Tumors were weighed and fixed in formalin for immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling analysis. Mcl-1 antisense oligonucleotides specifically reduced Mcl-1 protein expression but produced no reduction in tumor weigh...Continue Reading

References

Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H Edmonson
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K M KozopasR W Craig
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H EdmonsonD R Parkinson
Oct 1, 1996·The Journal of Surgical Research·T S TzaiN H Chow
Apr 19, 1997·Lancet·A WebbZ Dziewanowska
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W PistersR S Benjamin
Feb 14, 1998·Nature Medicine·B JansenH Pehamberger
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A ArndtJ S Miser
Jan 19, 2000·Trends in Pharmacological Sciences·K J Myers, N M Dean
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
Oct 19, 2000·Cancer Investigation·B P MoniaF A Dorr
Dec 29, 2000·Cellular and Molecular Life Sciences : CMLS·C AkgulS W Edwards
Mar 30, 2001·The Journal of Biological Chemistry·D D BannermanJ M Harlan
Jul 21, 2001·Cell Death and Differentiation·U K WiegandB A Spruce
Sep 20, 2001·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·K HiraokaA Inoue
Nov 3, 2001·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·V WacheckB Jansen
Mar 5, 2002·The Journal of Investigative Dermatology·Robert A OlieUwe Zangemeister-Wittke
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Elisabeth Heere-RessBurkhard Jansen
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Andreas EvdokiouDavid M Findlay
Nov 9, 2002·The Lancet Oncology·Burkhard Jansen, Uwe Zangemeister-Wittke
Apr 1, 2003·Acta Oncologica·Najme Wall, Hans Starkhammar
Jun 6, 2003·The Journal of Investigative Dermatology·Christiane ThallingerBurkhard Jansen

❮ Previous
Next ❯

Citations

Mar 21, 2006·Apoptosis : an International Journal on Programmed Cell Death·E MinetC Michiels
May 21, 2005·Nature Reviews. Cancer·Martin E Gleave, Brett P Monia
Jun 5, 2007·Current Opinion in Oncology·Bernd KasperAhmad Awada
Jan 16, 2009·Blood·Frank BreitenbuecherThomas Fischer
Feb 15, 2007·Expert Opinion on Therapeutic Targets·Arthur M Mandelin, Richard M Pope
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Dec 5, 2006·Critical Reviews in Oncology/hematology·Bernd KasperAhmad Awada
Mar 25, 2009·European Journal of Clinical Investigation·M WillmannE Selzer
Dec 9, 2004·Biochimica Et Biophysica Acta·Jeff CummingsCaroline Dive
Jul 22, 2008·Biochemical Pharmacology·Isabel Marzo, Javier Naval
Jan 18, 2006·International Journal of Radiation Oncology, Biology, Physics·Michael R HorsmanJolyon H Hendry
Dec 13, 2005·Cancer Treatment Reviews·Simone MocellinDonato Nitti
Nov 18, 2005·Journal of Hepatology·Wolfgang SieghartVolker Wacheck
Sep 13, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jing ZhangShufeng Zhou
Jun 17, 2015·BioMed Research International·Chunlin JiangMing Kuang
Dec 17, 2008·Journal of Experimental & Clinical Cancer Research : CR·Adrien DaigelerAnsgar M Chromik
Aug 31, 2006·International Review of Cytology·Peter HerseyX D Zhang
Apr 28, 2007·The Journal of Biological Chemistry·Shogo KobayashiGregory J Gores
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Hadi KaramiEbrahim Sakhinia
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth S HensonSpencer B Gibson
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Syed-Rehan A HussainJohn C Byrd

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis